{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:30:48Z","timestamp":1773289848558,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.01.021","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T09:58:23Z","timestamp":1738058303000},"page":"455-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Tony Z.","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.01.021_bib0001","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.021_bib0002","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0003","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0004","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2022-158631","article-title":"Five-year results and overall survival update from the phase 3 randomized study augment: lenalidomide plus rituximab (R2) vs rituximab plus placebo in patients with relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"140","author":"Leonard","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0006","first-page":"934","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018"},{"key":"10.1016\/j.clml.2025.01.021_bib0007","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.22.00843","article-title":"Six-year results from RELEVANCE: lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0008","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0009","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1182\/bloodadvances.2021005722","article-title":"Follicular lymphoma and macrophages: impact of approved and novel therapies","volume":"5","author":"Gouni","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.021_bib0010","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.021_bib0011","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/S2152-2650(23)00330-0","article-title":"EXABS-222-IBCL novel combinations in indolent lymphoma","volume":"23","author":"Strati","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.01.021_bib0012","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/bloodadvances.2022007104","article-title":"SIRP\u03b1+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab","volume":"6","author":"Marques-Piubelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.021_bib0013","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0014","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.01.021_bib0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific antibody use in patients with lymphoma and multiple myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2025.01.021_bib0017","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2023.41.16_suppl.7506","article-title":"Epcoritamab + R2regimen and responses in high-risk follicular lymphoma, regardless of POD24 status","volume":"41","author":"Merryman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0018","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2023-180092","article-title":"EPCORE FL-1: phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R 2) vs R 2 alone in patients with relapsed or refractory follicular lymphoma","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0019","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2023-174432","article-title":"Preliminary findings of a phase ib\/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with Lenalidomide (M+Len) in previously untreated (1L) follicular lymphoma (FL)","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7588","article-title":"A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL)","volume":"41","author":"Olszewski","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.clml.2025.01.021_bib0021","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.1182\/blood-2022-162538","article-title":"Evaluation of epcoritamab and rituximab combination in preclinical models of B-cell non-Hodgkin's lymphoma (NHL)","volume":"140","author":"Epling-Burnette","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0022","doi-asserted-by":"crossref","first-page":"TPS7588","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7588","article-title":"CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received \u2265 1 line of systemic therapy","volume":"40","author":"Nastoupil","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0023","doi-asserted-by":"crossref","first-page":"TPS7588","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7588","article-title":"A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL)","volume":"41","author":"Olszewski","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7588","article-title":"A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL)","volume":"41","author":"Olszewski","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.clml.2025.01.021_bib0025","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/blood-2022-159158","article-title":"Acalabrutinib plus Rituximab with or without lenalidomide in patients with follicular lymphoma: a multipart, open-label, phase 1b trial","volume":"140","author":"Strati","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0026","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971264.63302.14","article-title":"P1092: a phase ii investigator initiated study of acalabrutinib, lenalidomide and rituximab (AR2) in patients with previously untreated high tumor burden follicular lymphoma","volume":"7","author":"Strati","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2025.01.021_bib0027","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3324\/haematol.2021.279560","article-title":"The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact","volume":"107","author":"Pinney","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.01.021_bib0028","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","article-title":"Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma","volume":"4","author":"Tam","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.021_bib0029","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0030","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1200\/JCO.2023.41.16_suppl.7545","article-title":"Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed\/refractory follicular lymphoma: updated analysis of the ROSEWOOD study","volume":"41","author":"Flowers","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0031","doi-asserted-by":"crossref","first-page":"TPS7590","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7590","article-title":"MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0032","doi-asserted-by":"crossref","first-page":"CT037","DOI":"10.1158\/1538-7445.AM2024-CT037","article-title":"Abstract CT037: a phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"84","author":"Strati","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2025.01.021_bib0033","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0034","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1182\/blood-2023-179910","article-title":"Tazemetostat in combination with Lenalidomide and Rituximab in patients with relapsed\/refractory follicular lymphoma: updated phase 1b results of symphony-1 with 22.5 months follow-up","volume":"142","author":"Salles","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0035","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(21)00311-2","article-title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"8","author":"Diefenbach","year":"2021","journal-title":"Lancet Haematol"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2025.01.021_bib0036","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-212970","article-title":"Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.021_bib0037","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2024-199093","article-title":"Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed\/Refractory Follicular Lymphoma","volume":"144","author":"Alderuccio","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0038","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood-2023-178825","article-title":"Limited duration loncastuximab tesirine with rituximab induces high complete metabolic response rate in high-risk relapsed\/refractory follicular lymphoma-a phase 2 study","volume":"142","author":"Alderuccio","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0039","first-page":"P1132","article-title":"Safety and efficacy of golcadomide, a potential first-in-class celmod agent \u00b1 rituximab in a phase 1\/2 open-label study of patients with relapsed\/refractory (R\/R) follicular lymphoma (FL)","volume":"419219","author":"Chavez","year":"2024"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.021_bib0040","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood-2024-203131","article-title":"Golcadomide (GOLCA)\u00b1rituximab (RTX) demonstrates durable efficacy and is well tolerated in patients (pts) with relapsed\/refractory follicular lymphoma (R\/R FL): updated results from the phase 1\/2 CC-99282-NHL-001 study","volume":"144","author":"Chavez","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.01.021_bib0041","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7092","article-title":"First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab\u00b1nivolumab: an umbrella randomised phase 2 investigator-led study","volume":"24","author":"Chong","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.01.021_bib0042","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0043","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/blood-2019-130539","article-title":"A phase I study of Nivolumab and lenalidomide in relapsed\/refractory B cell lymphoma","volume":"134","author":"Bond","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.021_bib0044","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-203185","article-title":"Golseek-1: a Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP vs R-CHOP in Patients with Previously Untreated","volume":"144","author":"Hoffmann","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0045","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0046","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.01.021_bib0047","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0048","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.01.021_bib0049","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.021_bib0050","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2024-198509","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): transcend FL 2-year follow-up","volume":"144","author":"Nastoupil","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.021_bib0051","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2024-201730","article-title":"Clinical outcomes of patients with high-risk relapsed\/refractory follicular lymphoma treated with Tisagenlecleucel: phase 2 ELARA 4-year update","volume":"144","author":"Thieblemont","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0052","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0053","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.021_bib0054","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1200\/JCO.2021.39.15_suppl.7541","volume":"39","author":"Strati","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.021_bib0055","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1182\/blood-2021-151520","article-title":"Phase I study of FT516, an off-the-shelf iPSC-derived NK cell therapy, in combination with rituximab in patients with relapsed\/refractory B-cell lymphoma","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.021_bib0056","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2021-151185","article-title":"Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:50:47Z","timestamp":1749477047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000369"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}